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Clerodendron phlomidis Linn. (Verbenaceae) is known as
Agnimantha in sanskrit. Bark of the plant is used in treating various
nervous disorders. In the present study C. phlomidis was
investigated for its potential as a nootropic agent in mice. The
aqueous extract of the C. phlomidis (100 and 200 mg/kg, p.o.) was
administered for 6 successive days to both young and aged mice.
Exteroceptive behavioral models such as elevated plus maze and
passive avoidance paradigm were employed to evaluate short term
and long term memory respectively. Scopolamine (0.4 mg/kg, i.p.),
diazepam (1 mg/kg, i.p.) were employed to induce amnesia in mice.
To delineate the mechanism by which C. phlomidis exerts nootropic
action, its effect on brain acetyl cholinesterase levels were
determined. Piracetam (200 mg/kg, i.p.) was used as a standard
nootropic agent. Pretreatment with C. phlomidis (100 and 200 mg/
kg, p.o.) for 6 successive days significantly improved learning and
memory in mice. It reversed the amnesia induced by scopolamine,
diazepam and natural ageing. It also decreased the acetyl
cholinesterase levels in the whole brain. The bark of C. phlomidis
can be of enormous use in the management of treatment of cognitive
disorders such as amnesia and Alzheimer’s disease.
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INTRODUCTION
Neurodegenerative diseases are now generally
considered as a group of disorders that seriously and
progressively impair the functions of the nervous system
through selective neuronal vulnerability of specific brain
regions. Alzheimer’s disease (AD) is the most common
neurodegenerative disease (Scatena et al., 2007), which affects
the brain and hence memory. It is a chronic, progressive
organic brain disorder characterized by disturbance of multiple
cortical functions, including memory, judgement, orientation,
comprehension, learning capacity and language (Jay, 2005).
Clinically, the disorder is characterized by a gradual but
progressive decline in memory and other cognitive domains
and the frequent occurrence of noncognitive behavioral
symptoms. Neuropathologically, the cardinal features of AD
include neuritic plaques, neuro-fibrillary tangles, and the loss
of synapses and neurons (Caselli et al., 2006). AD has been
identified as a protein misfolding disease due to the
accumulation of abnormally folded amyloid beta protein in the
brains of AD patients (Hashimoto et al., 2003). Amyloid beta
(A²), is a short peptide that is an abnormal proteolytic
byproduct of the transmembrane protein amyloid precursor
protein (APP), whose function is unclear but thought to be
involved in neuronal development (Kerr, Small, 2005).
Neuropathogenesis is proposed to be a result of the
accumulation of amyloid beta peptides in the brain together
with oxidative stress mechanisms and neuroinflammation
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(Newman et al., 2006). AD begins as a deficiency in the
production of the neurotransmitter acetylcholine. Patients with
AD show loss of cognitive, intellectual,functional and social
abilities, and therefore become fully dependent on their
caregiver. It is estimated that in 2010 over five million people
will be diagnosed with probable AD in the United States alone.
Increasing age is the greatest risk factor for AD; one-tenth of
elderly over 65 years of age develop AD, whereas nearly half
of those over age 85 are diagnosed with probable AD. Certain
people in the population are at greater risk of developing AD
due to various genetic risk factors associated with AD such as
apolipoprotein (APO) polymorphism (Francesco et al., 2006).
A person with AD is expected to live an average of 8 years and
up to 20 years after the onset of symptoms. An association
between cholesterol and the development of AD was suggested
in the early 1990s and ever since, an increasing amount of
research has confirmed that there is a link between cholesterol
and the development of AD. A high cholesterol levels in mid-
life is a risk for AD (Sjogren et al., 2006). The National
Institute of Health predicts, if the current trend continues, there
will be more than 8.5 million AD patients by the year 2030 in
USA alone (Anonymous, 2000). Although there is no cure for
dementia of AD type at present, alternative pharmacologic
treatment modalities can reduce the symptoms of cognitive
impairment and slow disease progression (Geldmacher, 2003).
Nootropic agents like, piracetam and cholinesterase inhibitors
like, Donepezil® are commonly used for improving memory,
mood and behavior. However, the resulting adverse effects of
these drugs such as diarrhea, insomnia, nausea, bronchitis,
loose stools, muscular cramps and other known side effects
(Doody et al., 2001), has made their use limited and it is
worthwhile to explore the utility of traditional medicines in the
treatment of various cognitive disorders. In the early stages of
this neurodegenerative process it is more pronounced in
cholinergic-type brain centres. One of the most notable of these
is the amount of attention recently being paid to the enzyme
AChE, which increases the bioavailability of the
neurotransmitter in the cholinergic synapses by preventing the
hydrolysis of acetylcholine (Gandia et al., 2006). Herbal
medicines can be used in the treatment of AD (Izzo, Capasso,
2007). Higher intake of folate and vitamins B6 (pyridoxine
hydrochloride) and B12 (cyanocobalamin) may decrease the
risk of AD through the lowering of homocysteine levels
(Luchsinger et al., 2007).
Clerodendron phlomidis Linn. (verbenaceae) is
known as Agnimantha in Sanskrit. Bark of the plant is used
for treating various nervous disorders (Chopra, 1956). A
decoction of C. phlomidis leaves is used along with other
parts for inflammation and is effective in treating
bronchitis, headache, weakness, drowsiness and digestive
problems (Nadkarni, 1976). C. phlomidis has also shown
antidiarrhoeal activity (Rani et al., 1999) and antifungal
activity (Rajasekaran et al., 2006). A new chalcone
glycoside, together with pectolinarigenin,
7-hydroxyflavone and 7-hydroxyflavanone 7-O-glucoside
have been isolated from the flowers and leaves of C.
phlomidis (Roy, Pandey, 1994).
In the present study C. phlomidis was investigated
for its potential as a nootropic agent. Elevated plus maze
and passive avoidance paradigms were the exteroceptive
behavioral models to assess short-term and long term
memory respectively. To delineate the mechanism by which
C. phlomidis exerts nootropic action, its effects on brain
cholinesterase levels were also determined.
MATERIALS AND METHODS
The plant material
The bark of Clerodendron phlomidis (Family -
Verbenaceae) was obtained from Dharwad, Karnataka,
India. The plant was authenticated and identified by Dr. S.
Hebbar, taxonomist, Department of Botany, Karnatak
University, Dharwad. The specimen has been kept at Dept.
of Pharmacognosy, SET’S college of Pharmacy, Dharwad,
Karnataka, India.
Preparation of extract
The bark was dried in shade; cleaned, powdered and
aqueous extract was prepared by simple maceration
process using 1000 g of powder. The extract was
concentrated using rotary flash evaporator followed by
freeze drying. The yield of the dry extract from crude
powder of C. phlomidis was 2%. A suspension was
prepared using tween 80 and administered orally.
Drugs and chemicals
Scopolamine hydro bromide (Sigma Aldrich, USA),
diazepam (Valium®, Ranbaxy laboratories Ltd., Mumbai,
India), piracetam (Nootropil® UCB India pvt. Ltd., Vapi,
India) and phenytoin (Zydus Neurosciences, Ahmedabad,
India) were diluted in normal saline and injected
intraperitoneally (i.p.). Volume of injection was 1 ml/100 g
body weight of the mouse.
Animals
 Swiss mice of either sex weighing around 18 g
(younger, 8 weeks old) and 25 g (older, 28 weeks old) were
used in the present study. Animals were procured from
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disease free animal house, BLDEA Medical College,
Bijapur. They were acclimatized to the laboratory
conditions for 5 days before behavioral studies. The
animals had free access to food and water and maintained
under 12:12 h light and dark cycles. All experiments were
carried out during day time from 900 to1900 hours. The
Institutional Animals Ethics Committee (IAEC) approved
the experimental protocol and care of animals was taken as
per guidelines of CPCSEA, Dept. of Animal Welfare, Govt.
of India (Nº. 412).
MEMORY MODELS
Exteroceptive behavioral model
Elevated plus maze
The elevated plus maze served as the exteroceptive
behavioral model (where in stimulus existed outside the
body) to evaluate learning and memory in mice (Joshi,
Parle, 2006). The apparatus consists of two open arms (16
cm x 5 cm) and two covered arms (16 cm x 5 cm x 12 cm).
The arms extended from a central platform (5 cm x 5 cm),
and maze is elevated to a height of 25 cm from the floor. On
the first day, each mouse was placed at the end of open arm,
facing away from the central platform. Transfer latency
(TL) was taken as the time taken by mouse to move into one
of the covered arm with all its four legs. TL was recorded
on the first day. If the animal did not enter into one of the
covered arms within 90 sec, it is gently pushed into one of
the two covered arms and the TL was assigned as 90
seconds. The mouse was allowed to explore the maze for 10
seconds and then returned to its home cage. Memory
retention was examined on the second day, 24 hours after
the first day’s trial (Dhingra et al., 2004; Itoh et al., 1990;
Parle, Dhingra, 2003; Joshi et al., 2006).
Passive shock avoidance paradigm
Passive avoidance behavior based on negative
reinforcement was used to examine the long term memory.
The apparatus consisted of a box (27 x 27 x 27 cm) having
three walls of wood and one wall of Plexiglas, featuring a
grid floor ( 3 mm stainless steel rods set 8 mm apart), with
a wooden platform (10 x 7 x 1.7 cm) in the center of the grid
floor. The box was illuminated with a 15 W bulb during the
experimental period. Electric shock (20V AC) was
delivered to the grid floor. Training was carried out in two
similar sessions. Each mouse was gently placed on the
wooden platform set in the center of the grid floor. When the
mouse stepped down and placed on the wooden platform set
in the center of the grid floor. When the mouse stepped
down and placed all its paws on the grid floor, shocks wee
delivered for 15 sec and the step-down latency (SDL) was
recorded. SDL was defined as the time taken by the mouse
to step down from wooden platform to grid floor with its
entire paw on the grid floor. Animals showing SDL in the
range (2-15 sec) during the first test were used for the
second session and the retention test. The second-session
was carried out 90 min after the first test. When the animals
stepped down before 60 sec, electric shocks were delivered
for 15 sec. During the second test, animals were removed
from shock free zone if they did not step down for a period
of 60 sec. Retention was tested after 24 h in a similar
manner, except that the electric shocks were not applied to
the grid floor. Each mouse was again placed on the
platform, and the SDL was recorded, with an upper cut-off
time of 300 s (Joshi, Parle, 2005; Parle et al., 2004; Joshi,
Parle, 2006a).
Interoceptive behavioral models:
Scopolamine induced amnesia - Amnesia was
induced by administration of scopolamine hydrobromide on
6th day and the TL recorded. Retention was recorded after
24 hr. CP (100 and 200 mg/kg) and piracetam (200 mg/kg)
were administered for 6 days successively. On 7th day, after
45 min of administration of doses, scopolamine (0.4 mg/kg,
p.o.) was administered and TL and SDL noted after 45 min.
Diazepam induced amnesia – Diazepam (1mg/kg,
i.p.) was administered to young mice and TL was noted
after 45 min of injection on 6th day and after 24 hr. CP (100
and 200 mg/kg, p.o.) and piracetam (200 mg/kg, ip) were
administered for 6 successive days. After 60 min of
administration of the last dose on 6th day, diazepam was
administered. TL and SDL were noted after 45 min of
administration of diazepam and after 24 hr (Joshi, Parle,
2006 b).
Estimation of brain Acetyl cholinesterase (AChE) activity
On the 7th day the animals were euthanized by
cervical dislocation carefully to avoid any injuries to the
tissue. The whole brain AChE activity was measured using
the Ellman method (Ellman et al., 1961). The end point was
the formation of yellow color due to the reaction of
thiocholine with dithiobisnitrobenzoate ions. The rate of
formation of thiocholine from acetylcholine iodide in the
presence of tissue cholinesterase was measured using a
spectrophotometer. The sample was first treated with
5, 5’-dithionitrobenzoic acid (DTNB) and the optical
density (OD) of the yellow color compound formed during
the reaction at 412 nm every minute for a period of three
minutes was measured. Protein estimation was done using
Folin’s method. AChE activity was calculated using the
following formula:
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d O.D. x volume of assay (3ml)
R = ––––––––––––––––––––––––––––
E x mg of protein
Where R= Rate of enzyme activity in ‘n’ mole of
acetylcholine iodide hydrolyzed / minute / mg protein. d
O.D. = Change in absorbance / min and E = Extinction
coefficient = 13600 / M / cm.
Statistical Analysis
All the results were expressed as mean ± Standard
error. The data was analyzed using ANOVA followed by
Tukey- kramer test. P < 0.01 was considered as statistically
significant.
RESULTS
Acute toxicity studies
C. phlomidis aqueous extract at different doses (50-
1000 mg/kg) was administered orally to the mice with the
help of a specially designed oral needle connected to a
polythene tube. Mice, which received extracts in doses
above 1000 mg/kg, exhibited ptosis (dropping of upper
eyelids) and were found lethargic. The parameters such as
hyperactivity, grooming, convulsions, sedation,
hypothermia and mortality were observed. The doses
selected were 100 mg/kg and 200 mg/kg/day.
Effect on transfer latency (TL) using elevated plus maze
Aged mice showed higher transfer latency (TL) values
on first day and on second day (after 24 hr) as compared to
young mice, indicating impairment in learning and memory.
Piracetam (200 mg/kg, i.p.) pretreatment for 6 days
decreased TL on 6th day and after 24 hrs i.e. on 7th day as
compared to control, indicating improvement in both
learning and memory (Figure 1). Scopolamine (0.4 mg/kg)
and Diazepam (1 mg /kg) increased TL significantly (P <
0.05) in young mice on first day and second day as compared
to control, indicating impairment of memory (Figure 2).
 C. phlomidis (100 and 200 mg/kg, p.o.) decreased
the TL on 6th day and 7th day in young and aged mice
(P<0.05) when compared to control groups. Higher doses
of CP (200 mg/kg, p.o.) more significantly enhanced the
learning and memory of aged animals rather than the young
mice as reflected by marked decrease in TL on 6th and 7th
day when subjected to elevated plus maze tests. The higher
doses of CP pretreatment for 6 days successively to young
mice protected them against scopolamine, diazepam and
ageing induced amnesia.
Effect on SDL using Passive avoidance apparatus
C. phlomidis extract (200 mg/kg, p.o.) profoundly
increased SDL as compared to control group on second day
FIGURE 1 - Effect of C. phlomidis (CP) on transfer latencies of young and aged mice.
 All values are mean ± SEM : ANOVA followed by Tukey- Kramer test
 * denotes P<0.01 as compared to control (Young)
 a denotes P<0.001 as compared to control (Young)
 b denotes P< 0.01 as compared to control (Aged)
 c denotes P<0.001 as compared to control (Aged)
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indicating improvement in the memory of young mice.
Furthermore, this dose of C. phlomidis reversed diazepam
and scopolamine significantly decreased SDL on second
day indicating impairment of memory (Figure 3).
Effect on whole brain acetylcholinesterase (AChE)
activity
The whole brain AChE activity with phenytoin (12
mg/kg, p.o.) exhibited significant elevation to AChE
activity as compared to control and piracetam (200 mg/kg,
p.o.). C. phlomidis (200 mg/kg, p.o.) significantly reduced
AChE activity (Figure 4).
DISCUSSION
Alzheimer’s disease (AD) is a progressive disease of
the brain. It is a common type of dementia in the elderly,
which can have devastating outcomes on the diagnosed
patient, on the caregiver and family, and on society at large.
AD is a major cause of disability and mortality, and its
impact on health care costs, including direct and indirect
medical and social service costs, is estimated to be greater
than $100 billion per year. AD typically presents with an
insidious decline in memory that progresses to affect
language, visuospatial perception, calculations, and
executive functioning. Behavioral and psychiatric
symptoms are also frequent in AD (Yaari, Corey-Bloom,
2007). The treatment of AD is a clinical challenge (Gustavo
et al., 2006). Many other conditions can lead to similar
memory loss, confusion, agitation and metabolic
disturbances (Francesco et al., 2006). The symptoms of
dementia are oxidative damage, impaired
neurotransmission and degeneration of neuronal circuits in
the affected brain areas (Joshi, Parle, 2006a). Oxidative
damage accompanies AD, and cholinesterase inhibitors are
recommended for use in mild to moderate AD (Joshi, Parle,
2006b). In exteroceptive behavioral models, the stimulus
lies outside the body where as, it lies within the body in case
of interoceptive behavioral models. Passive avoidance
behavior is a classic paradigm to assess memory with
strong aversive component (Poirier, 2002), based on
negative reinforcement and is used in the present study to
examine long-term memory where as Elevated plus maze
was used to examine short term memory (Doody et al.,
2001). Interoceptive behavioral models such as
scopolamine and natural aging induced amnesia are widely
cited as models simulating human dementia in general and
AD in particular (Cahil et al., 1998). Modulation of brain
aging with complex extracts containing active
phytochemicals has been useful in the aging of wild type
rodents with encouraging results (Giacobini, 1998).
FIGURE 2 - Effect of C. phlomidis (CP) on transfer latencies of diazepam and scopolamine induced mice.
 All values are mean ± SEM : ANOVA followed by Tukey- Kramer test
 * denotes P<0.01 as compared to control (Young)
 a denotes P<0.01 as compared to diazepam treated mice
 b denotes P< 0.001 as compared to diazepam treated mice
 c denotes P<0.01 as compared to scopolamine treated mice
 d denotes P<0.001 as compared to scopolamine treated mice
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Neurodegenerative disorders, such as AD, are often
characterised by the degeneration of the cholinergic system.
Thus, the aim of many treatment regimens is to support this
system either by means of muscarinic agonists or by
inhibitors of acetylcholinesterase (AChE), the latter being
able to increase the concentration of acetylcholine
(Holzgrabe et al., 2007).
The present study indicates that C. phlomidis is a
potential anti-cholinesterase agent. It also possesses
nootropic activity in view of its facilitatory effect on retention
of acquired learning. Cognitive deterioration occurring in
patients with probably AD is associated with progressive loss
FIGURE 4 - Effect of C. phlomidis (CP) on acetylcholinesterase activity of young and aged mice.
All values are mean ± SEM : ANOVA followed by Tukey- Kramer test
 * denotes P<0.01 as compared to control (Young)
 a denotes P<0.001 as compared to control (Young)
 b denotes P< 0.01 as compared to control (Aged)
 c denotes P<0.001 as compared to control (Aged)
FIGURE 3 - Effect of C. phlomidis (CP) on step down latency of young and aged mice.
All values are mean ± SEM : ANOVA followed by Tukey- Kramer test
 * denotes P<0.01 as compared to control (Young)
 a denotes P<0.001 as compared to control (Young)
 b denotes P< 0.01 as compared to control (Aged)
 c denotes P<0.001 as compared to control (Aged)
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of cholinergic neurons and consequent decline in levels of
acetylcholine (Ach) in brain. Cholinergic deficits occur in the
brain of patients with AD and vascular dementia (Mckeith et
al., 2003; Tohgi et al., 1990;). Altered hippocampal
neurogenesis may also play a pathophysiological role in
neurodegenerative disorders such as AD (Elder et al., 2006).
Phenytoin is known to reduce hippocampal ACh
concentration and causes cognitive impairment (Sudha et al.,
2001). The aqueous extract of C. phlomidis significantly
inhibited the AChE activity in the whole brain homogenate
of mice, indicating its potential in the attenuation of learning
and memory deficits especially in aged mice. Considering the
lack and need of drugs with proven effectiveness in
improving learning and memory (Bhattacharya et al., 2000),
the specific memory improving effects of C. phlomidis
reported in the present study is of enormous interest and
deserves further investigations using more experimental
paradigms for further confirmation of memory improving
potential of C. phlomidis in the treatment of various
cognitive disorders.
CONCLUSION
Considering the lack and the need of the drugs with
proven effectiveness in improving learning and memory, the
specific memory improving, anticholinesterase and
anticholesterol effects of C. phlomidis can be of enormous
use in the management of preliminary symptoms of
dementia and Alzheimer’s disease.
RESUMO
Avaliação da atividade antiamnésica da casca de C.
phlomidis Linn. em camundongos
Clerodendron phlomidis Linn. (Verbenaceae) é conhecida
como Agnimantha em sânscrito. A casca da planta é uti-
lizada no tratamento de várias disfunções neurológicas.
No presente estudo, C. phlomidis foi investigada pelo seu
potencial como agente nootrópico em camundongos. O
extrato aquoso de C. phlomidis (100 e 200 mg/kg, p.o.) foi
administrado por seis dias consecutivos tanto para ca-
mundongos jovens quanto para idosos.  Modelos
comportamentais exteroceptivos, tais como labirinto em
cruz elevada e paradigma de esquiva passiva foram em-
pregados para avaliar memória recente e tardia, respec-
tivamente. Escopolamina (0,4 mg/kg i.p.), diazepam   (1
mg/kg i.p.) foram empregados para induzir amnésia em
camundongos. A fim de delinear o mecanismo pelo qual
C. phlomidis exerce ação nootrópica,  determinaram-se
seus efeitos nos níveis cerebrais de acetilcolinesterase.
Utilizau-se piracetam (200 mg/kg i.p.) como nootrópico
padrão. O pré-tratamento com C. phlomidis (100 e 200
mg/kg, p.o.) por seis dias sucessivos melhorou, significa-
tivamente, o aprendizado e a memória em camundongos.
Ela reverteu a amnésia induzida por escopolamina,
diazepam e pelo envelhecimento normal. Também, dimi-
nuíram-se os níveis de acetilcolinesteraseem todo o cére-
bro. A casca de C. phlomidis pode ser de grande uso no
tratamento de disfunções cognitivas, como amnésia e
doença de Alzheimer.
UNITERMOS: Doença de Alzheimer. Agente nootrópico.
Acetilcolinesterase. Clerodendron phlomidis.
ACKNOWLEDGEMENT
 The authors express deep sense of gratitude to the
management, SET’s College of Pharmacy, Dharwad,
Karnataka for providing the facilities. The authors are also
thankful to Ranbaxy, India, for the generous supply of
diazepam, UCB pvt. Ltd., India, for supply of piracetam
and Zydus Neurosciences, India for the supply of
phenytoin.
REFERENCES
NATIONAL INSTITUTE OF AGING-NATIONAL
INSTITUTES OF HEALTH. Progress Report on
Alzheimer’s disease: Taking the next steps. Washington:
National Institutes of Health, 2000. p.1154-1156.
BHATTACHARYA, S.K.; BHATTACHARYA, A.;
KUMAR, A.; GHOSAL, S. Antioxidant activity of
Bacopa monniera in rat frontal cortex, striatum and
hippocampus. PTR, Phytother. Res., v.14, n.p.174-179,
2000.
CAHIL, L.; BRIONI, J.; IZQUIERDO, I. Mechanisms of
emotional arousal and lasting declarative memory. Trends
Neurosci., v.21, n. p.294-299, 1998.
CASELLI, R. J.; BEACH, T.J.; YAARI, R.; REIMAN, E, M.
Alzheimer’s disease-a century later. J. Clin. Psychiatry,
v.67, n.11, p.1784-800, 2006.
CHOPRA, R.N. Glossary of Indian medicinal plants, CSIR,
New Delhi, 1956, 162-164p.
DHINGRA, D.; MILIND, P.; KULKARNI, S.K. Memory
enhancing activity of Glycyrrhiza glabra in mice. J.
Ethnopharmacol., v. 1, n. p. 361-365, 2004.
H. Joshi, K. Megeri724
DOODY, R.S.; STEVENS, J.C.; BECK, R.N.; DUBINSKY,
R.M.; KOYE, J.A.; GWYTHER, L. Practice parameters:
Management of dementia (an evidence based review)-
report of the quality standards subcommittee of the
American Academy of Neurology. Neurology, v.56, n. p.
1154-1166, 2001.
ELDER, G.A.; DE GASPERI, R.; GAMA SOSA, M. A.
Research update: neurogenesis in adult brain and
neuropsychiatric disorders. Mt. Sinai J. Med., v. 73, n.7,
p. 731-740, 2006.
ELLMAN, G.L.; COURTNEY, K.D.; VALENTINO, A.J.;
FEATHERSTONE, R.M. A new and rapid colourimetric
determination of acetylcholinestrase activity. Biochem.
Pharmacol., v.7, n. p. 88-95, 1961.
FRANCESCO, C.; AUDREY, M.N.; DAVID, R.M.;
ERCOLANO, M.;PAOLO, P. Evidence based research in
complementary and alternative medicine II: Treatment of
patients with Alzheimer’s disease. eCAM, v.3, n.4, p. 411-
424, 2006.
GANDIA, L.; ALVAREZ, R.M.; HERNANDEZ-GUIJO,
J.M.; GONZDEZ-RUBIO, J.M.; DE PASCULA, R.;
ROJO, J.;TAPIA, L. Anticholinesterases in the treatment
of Alzheimer’s disease. Rev. Neurol., v. 27, n.1, p. 471-
477, 2006.
GELDMACHER, D.S. Alzheimer’s disease: current
pharmacotherapy in the context of patient and family
needs. J. Am. Geriatr. Soc., v.51, n. p.89-95, 2003.
GIACOBINI, E. Invited review: Cholinesterase inhibitors for
Alzheimer’s disease therapy: from tacrine to future
applications. Neurochem. Int., v.32, n.5-6, p.413-419,
1998.
HASHIMOTO, M.; ROCKENSTEIN, E.; CREWS, L.;
MASLIAH, E. Role of protein aggregation in
mitochondrial dysfunction and neurodegeneration in
Alzheimer’s and Parkinson’s diseases. Neuromolecular.
Med., v.4 , n.1-2, p.21-36, 2003.
HOLZGRABE, U.; KAPKOVA, P.; ALPTUZUN, V.;
SCHEIBER, J.; KUGELMANN, E. Targetting
acetylcholinesterase to treat neurodegeneration. Expert
Opin. Ther. Targets, v.11, n.2, p.161-179, 2007.
ITOH, J.; NABESHIMA, T.; KAMEYAMA, T. Utility of an
elevated plus maze for the evaluation of nootropics,
scopolamine and electro convulsive shock.
Psychopharmacology, v.101, n. p.27-33, 1990.
IZZO, A.A.; CAPASSO, F. Herbal medicines to treat
Alzheimer’s disease. Trends Pharmacol. Sci., v. 28, n.2,
p.47-48, 2007.
JOSHI, H.; PARLE, M. Antiamnesic effects of Desmodium
gangeticum in mice. Yakugaku Zashshi, v. 126, n.2, p.14-
17, 2006.
JOSHI, H.; PARLE, M. Effects of piperine on memory and
behavior mediated via monoamine neurotransmitters. J.
Trad. Med., v. 2, n. p. 39-43, 2005a.
JOSHI, H.; PARLE, M. Evaluation of nootropic potential of
Ocimum Sanctum Linn. in mice. Ind. J. Expt. Biol., v.44,
n. p.133-136, 2006a.
JOSHI, H.; PARLE, M. Nardostachys jatamansi improves
learning and memory in mice. J. Med. Food, v. 9, n.1, p.
113-118, 2006b.
JOSHI, H.; PARLE, M. Evaluation of the antiamnesic effects
of Phyllanthus niruri in mice. Colomb. Med., v.38, n.2, p.
132-139, 2007a.
JOSHI, H.; PARLE, M. Antiamnesic potentials of
Foeniculum vulgare Linn. in mice. The Oriental
Pharmacy and Experimental Medicine, v.7, n.2, p. 121-
129, 2007b.
JOSHI, H.; PARLE, M. Management of dementia through
ayurvedic formulation brahmi rasayana BR-2T in mice.
Alzheimers Dement., v.1, n.7, p. 64, 2005b.
JOSHI, H.; Soumya, S.V.; Chauhan, J. Pharmacological
evidences for Anti-Alzheimer’s potentials of Sesbania
grandiflora in mice. Natural Products, v.3, n.3, p. 112-
118, 2007c.
JAY, M.E. Cholinesterase inhibitors in the treatment of
dementia. JAOA, v. 3, n. p. 145-158, 2005.
KERR. M.; SMALL, D. Cytoplasmic domain of the beta-
amyloid protein precursor of Alzheimer’s disease:
function, regulation of proteolysis, and implications for
drug development. J. Neurosci. Res., v. 80, n.2, p. 151-
159, 2005.
Antiamnesic evaluation of C. phlomidis Linn. Bark extract in mice 725
LEOPALDO, L.S.; MARIA, A.V.T.; PATRICIA, M.;
GUSTAVO, A.S. The use of herbal medicines in
Alzheimer’s disease- A systematic review. eCAM, v. 3,
n.34, p. 441-445, 2006.
LUCHSINGER, J.A.; TANG, M.X.; MILLER, J.; GREEN, R.;
MAYEUX, R. Relation of higher folate intake to lower
risk of Alzheimer’s disease in elderly. Arch Neurol., v.
64(1), p. 86-92, 2007.
MCKEITH, I.G.; BURNS, D.J.; BALLARD, C.G.;
COLLERTON, D.; JARROS, E.; MORRIS, C.M.
Dementia with lewy bodies. Semin. Clin.
Neuropsychiatry, v.51, p. 296-304, 2003.
NADKARNI, A.K. Indian Materia Medica. Popular
Prakashan.Bombay; 1976.
NEWMAN, M.; MUSGRAVE, F.I.; LARDELLI, M.
Alzheimer’s disease: Amyloidgenesis the presenilins and
animal models. Biochem Biophys Acta, v.1772, p.285-
297, 2007.
PARLE, M.; DHINGRA, D. Ascorbic acid: a promising
memory enhancer in mice. J. Pharmacol. Sci, v. 93, n. p.
129-135, 2003.
PARLE, M.; DHINGRA, D.; KULKARNI, S.K.
Improvement of mouse memory by Myristica fragrans
seeds. J. Med. Food, v. 7, p. 157-161, 2004.
 POIRIER, J. Evidence that the clinical effects of
cholinesterase inhibitors are related to potency and
targeting of action. Int. J. Clin. Pract. Suppl., v. 127, p. 6-
19, 2002.
RAJASEKARAN, A; PONNUSAMY, K. Antifungal activity
of Clerodendron. Inerme (L) and Clerodendron. Phlomidis
(L). Turk. J. Biol., v.30, n. p.139-142, 2006.
RANI, S.; AHAMED, N.; RAJARAM, S.; SALUJA, R.;
THENMOZHI, S.; MURUGESAN, T. Anti-diarrhoeal
evaluation of Clerodendrum phlomidis Linn.leaf extract in
rats. J. Ethnopharmacol., v.68, n. p.315-319, 1999.
ROY, R.; PANDEY, V.B. Achalcone glycoside from
Clerodendron phlomidis. Phytochemistry, v.37, n.6,
p.1775-6, 1994.
SCATENA, R.; MARTORONA, G.E.; BOTTANI, P.;
BOTTA, G.; PASTOVE, P.; GIARDINA, B. An update
of pharmacological approaches to neurodegenerative
diseases. Expert Opin. Investig. Drugs, v. 16, n.1, p.59-
72, 2007.
SJOGREN, M.; MIELXE, M.; GUSTAFSON, D.; ZANDI,
P.; SKOOG, I. Cholesterol and Alzheimer’s disease—is
there a relation. Mech. Ageing. Dev., v.127, n.2, p.138-47,
2006.
SUDHA, S.; MADEPALLI, K.; LAKSHMANA.;
PRADHAN, N. Chronic phenytoin induced impairment
of learning and memory with associated changes in brain
acetyl cholinesterase activity and monoamine levels.
Pharmacol. Biochem. Behav., v.52, n. p.119-124, 2001.
TOHGI, H.; ABE, T.; KIMURA, M.; SAHEKI, M.;
TAKAHASHI, S. Cerebrospinal fluid acetylcholine and
choline in vascular dementia of Binswanger and multiple
small infarct types as compared with Alzheimer type
dementia. J. Neural. Transm., v. 103, n. p. 1211-1220,
1990.
YAARI, R.; COREY-BLOOM, J. Alzheimer’s disease.
Semin. Neurol., v. 27, n.1, p. 32-41, 2007.
Recebido para publicação em 21 de janeiro de 2008
Aceito para publicação em 30 de julho de 2008
